EphA2 targeting pegylated Nanocarrier drug delivery system for treatment of lung cancer

Pharmaceutical Research

Volumn 31, Issue 10, 2014, Pages 2796-2809

  Patel, Apurva R ^a   Chougule, Mahavir ^b   Singh, Mandip ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b UNIVERSITY OF HAWAII AT HILO   (United States)

Author keywords

Cancer therapeutics; EphA2; Imaging; Nanoparticles; Tumor targeted delivery

Indexed keywords

1,1-BIS(3'-INDOLYL)-1-(4-BIPHENYL)METHANE; ANTINEOPLASTIC AGENT; DRUG CARRIER; EPHRIN RECEPTOR A2; INDOLE DERIVATIVE; LIGAND; MACROGOL DERIVATIVE; NANOPARTICLE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN BINDING;

AGONISTS; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; ENDOCYTOSIS; HUMAN; LUNG NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; ENDOCYTOSIS; HUMANS; INDOLES; LIGANDS; LUNG NEOPLASMS; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR TARGETED THERAPY; NANOPARTICLES; POLYETHYLENE GLYCOLS; PPAR GAMMA; PROTEIN BINDING; RECEPTOR, EPHA2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84931087105     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1377-4     Document Type: Article

References (48)

1. Fleming S, Lucas F, Schofield M. A therapeutic area review of oncology products and players. Expert Opin Emerg Drugs. 2001;6(2):317-29.
2. Douillard JY, Eckardt J, Scagliotti GV. Challenging the platinum combinations in the chemotherapy of NSCLC. Lung Cancer. 2002;38 Suppl 4:21-8.
3. Tseng CL, Wu SY, Wang WH, Peng CL, Lin FH, Lin CC, et al. Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. Biomaterials. 2008;29(20):3014-22.
4. Chintharlapalli S, Smith 3rd R, Samudio I, Zhang W, Safe S. 1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl)methanes induce peroxisome proliferator-activated receptor gamma-mediated growth inhibition, transactivation, and differentiation markers in colon cancer cells. Cancer Res. 2004;64(17):5994-6001.
5. Ichite N, Chougule MB, Jackson T, Fulzele SV, Safe S, Singh M. Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer. Clin Cancer Res. 2009;15(2):543-52.
6. Kassouf W, Chintharlapalli S, Abdelrahim M, Nelkin G, Safe S, Kamat AM. Inhibition of bladder tumor growth by 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor gamma agonists. Cancer Res. 2006;66(1):412-8.
7. Chintharlapalli S, Papineni S, Safe S. 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes inhibit colon cancer cell and tumor growth through PPARgamma-dependent and PPARgamma-independent pathways. Mol Cancer Ther. 2006;5(5):1362-70.
8. Su Y, Vanderlaag K, Ireland C, Ortiz J, Grage H, Safe S, et al. 1,1-Bis(3'-indolyl)-1-(p-biphenyl)methane inhibits basal-like breast cancer growth in athymic nude mice. Breast Cancer Res. 2007;9(4):R56.
9. Horn L, Visbal A, Leighl NB. Docetaxel in non-small cell lung cancer: impact on quality of life and pharmacoeconomics. Drugs Aging. 2007;24(5):411-28.
10. Wakelee H, Belani CP. Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist. 2005;10 Suppl 3:1-10.
11. van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs. 2001;19(2):125-41.
12. Engels FK, Mathot RA, Verweij J. Alternative drug formulations of docetaxel: a review. Anticancer Drugs. 2007;18(2):95-103.
13. Heath JR, Davis ME. Nanotechnology and cancer. Annu Rev Med. 2008;59:251-65.
14. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-60.
15. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 2007;25(12):563-70.
16. Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev. 2007;59(6):491-504.
17. Noblitt LW, Bangari DS, Shukla S, Knapp DW, Mohammed S, Kinch MS, et al. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Cancer Gene Ther. 2004;11(11):757-66.
18. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res. 2001;61(5):2301-6.
19. Brantley-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, Cates JM, et al. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest. 2008;118(1):64-78.
20. Vaught D, Brantley-Sieders DM, Chen J. Eph receptors in breast cancer: roles in tumor promotion and tumor suppression. Breast Cancer Res. 2008;10(6):217.
21. Brannan JM, Dong W, Prudkin L, Behrens C, Lotan R, Bekele BN, et al. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res. 2009;15(13):4423-30.
22. Kamat AA, Coffey D, Merritt WM, Nugent E, Urbauer D, Lin YG, et al. EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer. 2009;115(12):2684-92.
23. Holm R, de Putte GV, Suo Z, Lie AK, Kristensen GB. Expressions of EphA2 and EphrinA-1 in early squamous cell cervical carcinomas and their relation to prognosis. Int J Med Sci. 2008;5(3):121-6.
24. Herath NI, Spanevello MD, Sabesan S, Newton T, Cummings M, Duffy S, et al. Over-expression of Eph and ephrin genes in advanced ovarian cancer: ephrin gene expression correlates with shortened survival. BMC Cancer. 2006;6:144.
25. Yang P, Yuan W, He J, Wang J, Yu L, Jin X, et al. Overexpression of EphA2, MMP-9, and MVD-CD34 in hepatocellular carcinoma: implications for tumor progression and prognosis. Hepatol Res. 2009;39(12):1169-77.
26. Shao Z, Zhang WF, Chen XM, Shang ZJ. Expression of EphA2 and VEGF in squamous cell carcinoma of the tongue: correlation with the angiogenesis and clinical outcome. Oral Oncol. 2008;44(12):1110-7.
27. Fang WB, Brantley-Sieders DM, Hwang Y, Ham AJ, Chen J. Identification and functional analysis of phosphorylated tyrosine residues within EphA2 receptor tyrosine kinase. J Biol Chem. 2008;283(23):16017-26.
28. Scarberry KE, Dickerson EB, McDonald JF, Zhang ZJ. Magnetic nanoparticle-peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells. J Am Chem Soc. 2008;130(31):10258-62.
29. Koolpe M, Dail M, Pasquale EB. An ephrin mimetic peptide that selectively targets the EphA2 receptor. J Biol Chem. 2002;277(49):46974-9.
30. Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, et al. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2009;101(17):1193-205.
31. Afar DE, Bhaskar V, Ibsen E, Breinberg D, Henshall SM, Kench JG, et al. Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. Mol Cancer Ther. 2004;3(8):921-32.
32. Qin C, Morrow D, Stewart J, Spencer K, Porter W, Smith 3rd R, et al. A new class of peroxisome proliferator-activated receptor gamma (PPARgamma) agonists that inhibit growth of breast cancer cells: 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes. Mol Cancer Ther. 2004;3(3):247-60.
33. Patel AR, Chougule MB, Townley I, Patlolla R, Wang G, Singh M. Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel. Pharm Res. 2013;30(5):1435-46.
34. Patlolla RR, Chougule M, Patel AR, Jackson T, Tata PN, Singh M. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Control Release. 2010;144(2):233-41.
35. Patlolla RR, Desai PR, Belay K, Singh MS. Translocation of cell penetrating peptide engrafted nanoparticles across skin layers. Biomaterials. 2010;31(21):5598-607.
36. Patel AR, Spencer SD, Chougule MB, Safe S, Singh M. Pharmacokinetic evaluation and in vitro-in vivo correlation (IVIVC) of novel methylene-substituted 3,3' diindolylmethane (DIM). Eur J Pharm Sci. 2012;46(1-2):8-16.
37. Lim SM, Kim TH, Jiang HH, Park CW, Lee S, Chen X, et al. Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles. Biomaterials. 2011;32(13):3538-46.
38. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53(2):283-318.
39. Zhu S, Hong M, Tang G, Qian L, Lin J, Jiang Y, et al. Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style. Biomaterials. 2010;31(6):1360-71.
40. Fang YP, Wu PC, Huang YB, Tzeng CC, Chen YL, Hung YH, et al. Modification of polyethylene glycol onto solid lipid nanoparticles encapsulating a novel chemotherapeutic agent (PK-L4) to enhance solubility for injection delivery. Int J Nanomedicine. 2012;7:4995-5005.
41. Wang JL, Liu YL, Li Y, Dai WB, Guo ZM, Wang ZH, et al. EphA2 targeted doxorubicin stealth liposomes as a therapy system for choroidal neovascularization in rats. Invest Ophthalmol Vis Sci. 2012;53(11):7348-57.
42. Wykosky J, Gibo DM, Debinski W. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. Mol Cancer Ther. 2007;6(12 Pt 1):3208-18.
43. Sun XL, Xu ZM, Ke YQ, Hu CC, Wang SY, Ling GQ, et al. Molecular targeting of malignant glioma cells with an EphA2-specific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells. Cancer Lett. 2011;312(2):168-77.
44. Jackson D, Gooya J, Mao S, Kinneer K, Xu L, Camara M, et al. A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res. 2008;68(22):9367-74.
45. Wang S, Placzek WJ, Stebbins JL, Mitra S, Noberini R, Koolpe M, et al. Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells. J Med Chem. 2012;55(5):2427-36.
46. Noberini R, Lamberto I, Pasquale EB. Targeting Eph receptors with peptides and small molecules: progress and challenges. Semin Cell Dev Biol. 2012;23(1):51-7.
47. Ichite N, Chougule M, Patel AR, Jackson T, Safe S, Singh M. Inhalation delivery of a novel diindolylmethane derivative for the treatment of lung cancer. Mol Cancer Ther. 2010;9(11):3003-14.
48. Weibo C, Alireza E, Kai C, Qizhen C, Zi-Bo L, David AT, Xiaoyuan C. Quantitative radioimmuno PET imaging of EphA2 in tumor-bearing mice. Eur J Nucl Med Mol Imag. 2007;34(12):2024-2036.